Psoriasis and Psoriatic Arthritis: How to Treat in the Era of Biologics and Small Molecule Inhibitors?

Psoriasis with psoriatic arthritis is a chronic and difficult-to-treat inflammatory skin condition. Recent developments in biology, immunology, and molecular biology have enabled us to use various targeted therapeutics in treating these conditions, such as biologics and small-molecule inhibitors. The enhanced speed at which translational research is developing in this field has led to the production of many biologics technologies and small-molecule inhibitors, but a complete cure for this condition has not yet been accomplished. In light of this, understanding the pathophysiology of these conditions is crucial and would allow us to carefully recognize which patients need to be treated earlier in order to improve patients’ quality of life. This Special Issue is composed of discussions on the pathophysiology of psoriasis with psoriatic arthritis, including infiltrating effector T-cells, regulatory T-cells, dendritic cells, monocytes, and macrophages; the treatment of psoriasis with psoriatic arthritis, including biologics, small-molecule inhibitors, and topical treatments; and the quality of life of patients with this condition, which includes the introduction of treatment goals and the treat-to-target concept.